John Zeeman

I build and scale biotechnology companies through machine learning, engineering, and strategy.

MIT Leaders for Global Operations (MBA + SM, Chemical Engineering). Previously Deloitte Cell and Gene Therapy and Amgen.

Get in touch Resume

Build

Cut experimentation 54 percent at Amgen

Built the hybrid mechanistic and machine learning framework behind more than $725K in annual site savings and faster study cycles.

Strategy

Grew Deloitte's cell and gene therapy practice 2.5x

Advised biotech and health-tech clients on launch plans and operating models, growing the practice from $100M to $250M.

Operate

MBA and SM in Chemical Engineering, together

Trained through MIT Leaders for Global Operations, built around operations leadership in technical industries.

In Chicago after graduate school, moving to Cambridge, MA in August 2026. Interested in AI-enabled biomanufacturing, synthetic biology, and building deep-tech startups.